276 related articles for article (PubMed ID: 33602299)
1. The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients.
Deegan P; Khan A; Camelo JS; Batista JL; Weinreb N
Orphanet J Rare Dis; 2021 Feb; 16(1):92. PubMed ID: 33602299
[TBL] [Abstract][Full Text] [Related]
2. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Mistry PK; Batista JL; Andersson HC; Balwani M; Burrow TA; Charrow J; Kaplan P; Khan A; Kishnani PS; Kolodny EH; Rosenbloom B; Scott CR; Weinreb N
Am J Hematol; 2017 Sep; 92(9):929-939. PubMed ID: 28569047
[TBL] [Abstract][Full Text] [Related]
3. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
4. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
Mistry PK; Deegan P; Vellodi A; Cole JA; Yeh M; Weinreb NJ
Br J Haematol; 2009 Nov; 147(4):561-70. PubMed ID: 19732054
[TBL] [Abstract][Full Text] [Related]
5. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
Weinreb NJ; Camelo JS; Charrow J; McClain MR; Mistry P; Belmatoug N;
Mol Genet Metab; 2021 Feb; 132(2):100-111. PubMed ID: 33485799
[TBL] [Abstract][Full Text] [Related]
6. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T
Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800
[TBL] [Abstract][Full Text] [Related]
7. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
8. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
Zimran A; Morris E; Mengel E; Kaplan P; Belmatoug N; Hughes DA; Malinova V; Heitner R; Sobreira E; Mrsić M; Granovsky-Grisaru S; Amato D; vom Dahl S
Blood Cells Mol Dis; 2009; 43(3):264-88. PubMed ID: 19502088
[TBL] [Abstract][Full Text] [Related]
9. Baseline characteristics of 32 patients with Gaucher disease who were treated with imiglucerase: South African data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Sevittz H; Laher F; Varughese ST; Nel M; McMaster A; Jacobson BF
S Afr Med J; 2022 Feb; 112(1):13518. PubMed ID: 35140000
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.
Weinreb NJ; Goldblatt J; Villalobos J; Charrow J; Cole JA; Kerstenetzky M; vom Dahl S; Hollak C
J Inherit Metab Dis; 2013 May; 36(3):543-53. PubMed ID: 22976765
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
Giraldo P; Irún P; Alfonso P; Dalmau J; Fernández-Galán MA; Figueredo A; Hernández-Rivas JM; Julia A; Luño E; Marín-Jimenez F; Martín-Nuñez G; Montserrat JL; de la Serna J; Vidaller A; Villalón L; Pocovi M
Blood Cells Mol Dis; 2011 Jan; 46(1):115-8. PubMed ID: 20934891
[TBL] [Abstract][Full Text] [Related]
12. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
13. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
Andersson H; Kaplan P; Kacena K; Yee J
Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
[TBL] [Abstract][Full Text] [Related]
14. Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: A sub-study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Cappellini MD; Carubbi F; Di Rocco M; Giona F; Giuffrida G
Blood Cells Mol Dis; 2023 Jan; 98():102705. PubMed ID: 36327675
[TBL] [Abstract][Full Text] [Related]
15. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.
Stirnemann J; Rose C; Serratrice C; Dalbies F; Lidove O; Masseau A; Pers YM; Baron C; Belmatoug N
Orphanet J Rare Dis; 2015 May; 10():62. PubMed ID: 25968608
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy with imiglucerase in a Taiwanese child with type 1 Gaucher disease.
Lin HY; Lin SP; Chuang CK; Wraith JE
J Chin Med Assoc; 2006 May; 69(5):228-32. PubMed ID: 16835986
[TBL] [Abstract][Full Text] [Related]
17. Effects of imiglucerase treatment on traumatic fracture and bone and blood abnormalities in a patient with previously untreated type 1 gaucher disease.
Boiret-Dupré N; Descamps S; Coudoré MA; Rapatel C; Kuentz M; Pereira S; Tournadre J; Berger J; Morell P; Berger MG
Clin Ther; 2009 Dec; 31(12):2900-4. PubMed ID: 20110029
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
Hollak CE; Belmatoug N; Cole JA; Vom Dahl S; Deegan PB; Goldblatt J; Rosenbloom B; van Dussen L; Tylki-Szymańska A; Weinreb NJ; Zimran A; Cappellini MD
Br J Haematol; 2012 Aug; 158(4):528-38. PubMed ID: 22640238
[TBL] [Abstract][Full Text] [Related]
19. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
20. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
